“…All fi rst and second drug choices, including miltefosine, have high toxicity, require parenteral use, have high rates of relapse and drug resistance, and ultimately lead to treatment failure, especially in immunocompromised patients who desperately require new therapies 3 . Miltefosine (hexadecylphosphocholine) is an alkylphosphocholine, originally developed for the treatment of cancer, which was discovered to possess antifungal, antiamoebic, and leishmanicidal activity 4,5 . The drug exerts its cytotoxic effect by interfering with the metabolism of membrane phospholipids, altering the composition, permeability, stability, and fluidity of the cell membrane, subsequently inducing apoptos is 3,6 .…”